In a press release from November 2023, the company announced that they were bringing lawsuits against two compounding pharmacies for selling adulterated and misbranded compounded drugs claiming to contain semaglutide. In a statement to Healthline, a Novo Nordisk representative said: To date, Novo Nordisk has filed a total of 12 legal actions against medical spas, weight loss or medical clinics, and compounding pharmacies to cease and desist from false advertising, trademark infringement and unlawful sales of non-FDA approved compounded products claiming to contain semaglutide
And it does not account for the fact that purity and concentration in unregulated peptides are not guaranteed
Mock DM
To date, metabolic bariatric surgery remains the most effective and long-lasting option for treating type 2 diabetes and obesity
Legacy weight and metabolic care platforms like Noom, Omada Health, and WeightWatchers that expanded into GLP-1 prescribing
If approved, Retatrutide could potentially contribute to the management of overweight and obesity
